# Psyadon Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/psyadon-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Germantown, US
- Website: www.psyadonrx.com
- Total disclosed funding: $11M
- Latest round: Series A (Nov 10, 2008)
- Investors on record: 3

## About

Psyadon Pharmaceuticals, Inc. is a Germantown-based company specializing in innovative penile enhancement procedures, offering minimally invasive glans enlargement treatments through hyaluronic acid injections.Founded in 2004 in Germantown, US, Psyadon Pharmaceuticals focuses on developing aesthetic solutions for male enhancement. The company raised USD 8.00 mn in Series A funding from New Enterprise Associates on November 10, 2008, and has completed a total of 2 deals since its inception.The company specializes in penile enhancement procedures, specifically focusing on glans enlargement through the injection of hyaluronic acid. This minimally invasive treatment increases both the size and firmness of the glans, typically lasting about 10 minutes. Clients enjoy a discreet enhancement with no downtime, enabling them to shower on the same day. Each procedure involves a thorough consultation for customization based on desired outcomes and budget, targeting adult males concerned with penile size and sensitivity, particularly in regions like Japan and East Asia where such procedures are becoming increasingly accepted.Psyadon Pharmaceuticals generates revenue through direct transactions with clients seeking glans enlargement services. Each procedure is priced per injection, with clients typically purchasing one to two syringes of hyaluronic acid per session. The company operates on a direct-to-consumer model, providing services through its clinics where customers receive personalized treatment plans. The revenue is derived from individual treatment fees rather than subscriptions or partnerships, with offerings positioned as premium services aimed at enhancing male confidence and sexual satisfaction.Psyadon Pharmaceuticals is focused on expanding its product offerings and market reach. The company is designing new enhancements to complement its existing glans enlargement procedure, though specific release dates have not been disclosed. Additionally, Psyadon aims to enter new markets, particularly targeting regions in East Asia, by 2025 to capitalize on the growing acceptance of aesthetic procedures. The recent funding of USD 8.00 mn from Series A financing will support these initiatives, including product development and market expansion efforts.

## Funding rounds

- Series A, Nov 10, 2008, $8M — New Enterprise Associates
- Series A, Jun 21, 2007, $3M — Domain Associates, New Enterprise Associates, Aberdare Ventures

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- Aberdare Ventures (https://capitalatlas.ai/funds/aberdare-ventures) — Series A